Congenic DIA dopamine receptor mutants: Ethologically based resolution of behavioural topography indicatesgenetic background as a determinant of knockout phenotype

Neuropsychopharmacology

Volumn 28, Issue 1, 2003, Pages 86-99

  McNamara, Fergal N ^a   Clifford, Jeremiah J ^a   Tighe, Orna ^a   Kinsella, Anthony ^b   Drago, John ^c   Croke, David T ^a   Waddington, John L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Behaviouralphenotype; Congenic DIA knockout; Dopamine DIA receptor; Ethogram; Genetic background; Targeted gene deletion; Topographicalassessment

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BENZAMIDE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE D1A RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; EMONAPRIDE; N N PROPYL N PHENYLETHYL 4(3 HYDROXYPHENYL)ETHYLAMINE HYDROCHLORIDE; N-N-PROPYL-N-PHENYLETHYL-4(3-HYDROXYPHENYL)ETHYLAMINE HYDROCHLORIDE; PHENETHYLAMINE DERIVATIVE; SK&F 83959;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; C57BL MOUSE; CONGENIC STRAIN; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EXPLORATORY BEHAVIOR; GENETICS; HABITUATION; MOTOR ACTIVITY; MOUSE; MOUSE MUTANT; MUTATION; PHENOTYPE; PHYSIOLOGY; TRANSGENE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANIMALS, CONGENIC; BEHAVIOR, ANIMAL; BENZAMIDES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; EXPLORATORY BEHAVIOR; HABITUATION, PSYCHOPHYSIOLOGIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MUTATION; PHENETHYLAMINES; PHENOTYPE; RECEPTORS, DOPAMINE D1; TRANSGENES;

EID: 0037208933     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300008     Document Type: Article

References (36)

1. Andringa G, Drukarch B, Leysen JE, Cools AR, Stoof JC (1999). The alleged dopamine D1 receptor agonist SKF 83959 is a dopamineD1 receptor antagonist in primate cells and interacts with otherreceptors.Eur J Pharmacol364: 33-41.
2. Arnt J, Hyttel J, Sanchez C (1992). Partial and full dopamine D1 receptor agonists in mice and rats: relation between behaviouraleffects and stimulation of adenylatecyclase activityin vitro. EurJ Pharmacol213: 259-267.
3. Carter TA, Del Rio JA, Greenhall JA, Latronica ML, Lockhart DJ, Barlow C (2001).Chipping away at complex behavior: tran-scriptome/phenotype correlations in the mouse brain.PhysiolBehav73: 849-857.
4. Clifford JJ, Kinsella A, Tighe O, Rubinstein M, Grandy DK, Low MJet al(2001). Comparative, topographically based evaluation ofbehavioural phenotype and specification of D1-like:D2-likeinteractions in a line of incipient congenic mice with D2dopamine receptor ‘knockout’.Neuropsychopharmacology25:527-536.
5. Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL (1998). Topographical evaluation of the phenotype of sponta-neousbehaviour in mice with targeted gene deletion of the D1Adopamine receptor: paradoxical elevation of grooming syntax.Neuropharmacology37: 1595-1602.
6. Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, Drago Jet al (1999). Conservation of behavioural topography to dopamineD1-like receptor agonists in mutant mice lacking the D1Areceptor implicates a D1-like receptor not coupled to adenylylcyclase.Neuroscience93: 1483-1489.
7. Clifford JJ, Usiello A, Vallone D, Kinsella A, Borrelli E, Waddington JL (2000). Topographical evaluation of behaviouralphenotype in a line of mice with targeted gene deletion of the D2dopamine receptor.Neuropharmacology39: 382-390.
8. Crabbe JC, Wahlsten D, Dudek BC (1999). Genetics of mouse behavior: interactions with laboratory environment.Science284:1670-1672.
9. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson Net al(1997). Behavioral phenotypes of inbredmouse strains: implications and recommendations for molecularstudies.Psychopharmacology132: 107-124.
10. Cromwell HC, Berridge KC, Drago J, Levine MS (1998). Action sequencing is impaired in D1A-deficient mutant mice.Eur JNeurosci10: 2426-2432.
11. Deveney AM, Waddington JL (1995). Pharmacological character-ization of behavioural responses to SKF 83959 in relation to ‘D1-like’ dopamine receptors not linked to adenylyl cyclase.Br JPharmacol116: 2120-2126.
12. Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PEet al(1994). Altered striatal function in a mutant mouselacking D1A dopamine receptors.ProcNatlAcadSci USA91:12564-12568.
13. Gerlai R (1996). Gene-targeting studies of mammalian behaviour: is it the mutation or the background genotype.Trends Neurosci19: 177-181.
14. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995). Stimulation of adenylatecyclase activity by benzazepine D-1dopamine agonists with varying efficacies in the 6-hydroxydo-pamine lesioned rat-relationship to circling behaviour.Bio-chemPharmacol49: 1185-1193.
15. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang Get al(1998). Locomotor activity in D2 dopaminereceptor-deficient mice is determined by gene dosage, geneticbackground, and developmental adaptations.J Neurosci18:3470-3479.
16. Kido Y, Philippe N, Schaffer AA, Accilli D (2000). Genetic modifiers of the insulin resistance phenotype in mice.Diabetes49: 589-596.
17. Lariviere WR, Chesler EJ, Mogil JS (2001). Transgenic studies of pain and analgesia: mutation or background genotype?JPharmacolExpTher297: 467-473.
18. Mahan LC, Burch RM, MonsmaJr FJ, Sibley DR (1990). Expression of striatal D1 dopamine receptors coupled to inositol phosphateproduction and Ca2mobilization in Xenopus oocytes.ProcNatlAcadSci USA87: 2196-2200.
19. Moratalla R, Xu M, Tonegawa S, Graybiel AM (1996). Cellular responses to psychomotor stimulant and neuroleptic drugs areabnormal in mice lacking the D1 dopamine receptor.ProcNatlAcadSci USA93: 14928-14933.
20. Nadeau JH (2001). Modifier genes in mice and humans.Nat Rev Genet2: 165-174.
21. Niznik HB, Sugamori KS, Clifford JJ, Waddington JL (2002). D1-like dopamine receptors: molecular biology and pharmaco-logy. In: Di Chiara G (ed).Handbook of ExperimentalPharmacology: Dopamine in the CNS.Springer: Heidelberg,121-158.
22. Panchalingham S, Undie AS (2001). SKF 83959 exhibits biochem-icalagonism by stimulating [35S]GTPgS binding and phos-phoinositide hydrolysis in rat and monkey brain.Neurophar-macology40: 826-837.
23. Phillips TJ, Hen R, Crabbe JC (1999). Complications associated with genetic background effects in research using knockoutmice.Psychopharmacology (Berl)147: 5-7.
24. Ralph RJ, Paulus MP, Geyer MA (2001). Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotorbehavior in mice.J PharmacolExpTher298: 148-155.
25. Rogers DC, Jones DN, Nelson PR, Jones CM, Quilter CA, Robinson TLet al(1999). Use of SHIRPA and discriminantanalysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains.Behav Brain Res105: 207-217.
26. Sandberg R, Yasuda R, Pankratz DG, Carter TA, Del Rio JA, Wodicka Let al(2000). Regional and strain-specific geneexpression mapping in the adult mouse brain.ProcNatlAcadSciUSA97: 11038-11043.
27. Sanford LP, Kallapur S, Ormsby I, Doetschman T (2001). Influence of genetic background on knockout mouse phenotypes. In:Tymms MJ, Kola I (eds).Gene Knockout Protocols.HumanaPress Inc: Totowa, NJ, 217-226.
28. Sibley DR (1999). New insights into dopaminergic receptor function using antisense and genetically altered animals.AnnuRev PharmacolToxicol39: 313-341.
29. Smith DR, Striplin CD, Geller AM, Mailman RB, Drago J, Lawler CPet al(1998). Behavioural assessment of mice lacking D1Adopamine receptors.Neuroscience86: 135-146.
30. Undie AS, Friedman E (1990). Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain.JPharmacolExpTher253: 987-992.
31. Undie AS, Weinstock J, Sarau HM, Friedman E (1994). Evidence for a distinct D1-like dopamine receptor that couples toactivation of phosphoinositide metabolism in brain.J Neuro-chem62: 2045-2048.
32. Waddington JL, Clifford JJ, McNamara FN, Tomiyama K, Koshikawa N, Croke DT (2001). The psychopharmacology-molecular biology interface: exploring the behavioural roles ofdopamine receptor subtypes using targeted gene deletion(‘knockout’).ProgNeuropsychopharmacolBiol Psychiatry25:925-964.
33. Waddington JL, Daly SA, McCauley PG, O’Boyle KM (1994). Levels of functional interaction between D1-like and D2-like dopaminereceptor systems. In: Niznik HB (ed).Dopamine Receptors andTransporters. Marcel Dekker: New York, 511-537.
34. Waddington JL, Deveney AM, Clifford J, Tighe O, Croke DT, Sibley DRet al(1998). D1-like dopamine receptors: regulation ofpsychomotor behaviour, D1-like:D2-like interactions andeffects of D1A targeted gene deletion. In: Jenner P, DemirdamarR (eds).Dopamine Receptor Subtypes.IOS Press: Amsterdam,45-53.
35. Xu M, Hu XT, Cooper DC, Moratalla R, Graybiel AM, White FJet al(1994a). Elimination of cocaine-induced hyperactivity anddopamine-mediated neurophysiological effects in dopamine D1receptor mutant mice.Cell79: 945-955.
36. Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AMet al(1994b). Dopamine D1 receptor mutant mice are deficient instriatal expression of dynorphin and in dopamine-mediatedbehavioral responses.Cell79: 729-742.